Rheumatoid Arthritis with Contraindication or Intolerance to Methotrexate and Elevated Rheumatoid Factor
When methotrexate cannot be used — due to a contraindication or early intolerance — and poor prognostic features are present, a specific first-line treatment strategy applies. This page outlines the clinical scenario and the goals of care; the full structured regimen is available via the link below.
Clinical Scenario
Elevated Rheumatoid Factor / ACPA
Methotrexate is not an option, and one or more of the following poor prognostic factors are present:
- Positive RF and/or ACPA, especially at high levels
- Persistently moderate or high disease activity despite csDMARD therapy
- High swollen joint count
- High acute-phase reactant levels
- Presence of early erosions
- Failure of 2 or more csDMARDs
Treatment Approach — Partial Overview
An alternative conventional synthetic DMARD serves as the foundation of the first treatment strategy, combined with a short-term course of glucocorticoids as bridging therapy, tapered and discontinued as quickly as clinically feasible.
The specific agent, dosing, route, duration, and escalation criteria are detailed in the full structured protocol.
Treatment Goals
The target is at least 50% improvement in disease activity within 3 months, with sustained remission or low disease activity reached by 6 months. If the target is not achieved, therapy is adjusted.
References
DOI: 10.1136/ard-2022-223356
- In patients with a contraindication to MTX (or early intolerance), leflunomide or sulfasalazine should be considered as part of the (first) treatment strategy.
- Short-term glucocorticoids should be considered when initiating or changing csDMARDs, in different dose regimens and routes of administration, but should be tapered and discontinued as rapidly as clinically feasible.
- Presence of RF and/or ACPA, especially at high levels.
- Presence of early erosions.
- Failure of 2 or more csDMARDs.
- Treatment should be aimed at reaching a target of sustained remission or low disease activity in every patient.
- Monitoring should be frequent in active disease (every 1–3 months); if there is no improvement by at most 3 months after the start of treatment or the target has not been reached by 6 months, therapy should be adjusted.
View source ↗